focus -WSS

focus

author：explore 2025-10-01 14:20:02 - browse：26333

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Physician assistants need a new name. Here's what it should be

focus

WSS

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Profiling embryos to choose those with higher IQs is almost a reality

Problems with a popular proposal to regulate AI in health care

Readout LOUD: Venture capital, Gilead, and more M&A

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Unique patient identifier: Experts argue the benefits, pitfalls

explore

focus

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Boston Scientific acquires urology company Axonics for $3.7 billion

Alkermes shareholders re

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

State Dept. review finds Biden bears some blame for Afghanistan failures

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

BioMarin wins approval for gene therapy to treat hemophilia A

Texas Medical Board asked to define abortion emergency exception

Duchenne breakthrough therapy leaves behind pioneering families

STAT Virtual Event: JPM Recap, Live!

knowledge

Unique patient identifier: Experts argue the benefits, pitfalls

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Top private equity targets in 2023: cardiology, clinical trials, lasers

Male doctors called my cancer incurable. A female doctor showed it wasn't

Profiling embryos to choose those with higher IQs is almost a reality

JPM pitch from hospitals? Revenue streams outside of patient care

explore

focus

focus

hotspot